DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07229170

GLP1-TASTE

Recruiting

Changes in Taste and Eating Habits Associated With GLP-1 Agonists in Weight Loss Patients

Changes in Taste Perception, Eating Habits, and Other Behavioral Aspects Associated With the Use of GLP-1 Receptor Agonists in Patients Undergoing Weight Loss Treatment: A Retrospective Observational Study.

Assets

GLP-1 / incretin class catch-all / Semaglutide / Tirzepatide

Listed sites

4

Recruiting sites

3

Enrollment

150

estimated

Study population

Obesity / overweight

Key I/E criterion

—

Primary endpoint

•Taste perception and food preferences

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07229170
Org study IDGLP1-TASTE

Timeline

Milestones

Study first posted2025-11-14actual
Study start2025-12-01actual
Last update posted2026-04-28actual
Primary completion2027-01-01estimated
Study completion2028-01-01estimated

Assets

Investigational agents

GLP-1 / incretin class catch-allSemaglutideTirzepatide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
Maximum age60 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

Adults with obesity receiving GLP-1 agonist treatment at specialized nutrition centers in Italy, assessed retrospectively.

Eligibility criteria

Inclusion: Adults aged 18-60 years diagnosed with obesity and undergoing treatment with GLP-1 receptor agonists such as semaglutide or tirzepatide. Must have clinical records and dietary data available for at least 12 weeks of treatment.

Exclusion: Patients with conditions affecting taste independent of GLP-1 treatment, severe comorbidities, or inability to provide consent and data.

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK
2
Weight & body composition
1
Other clinical outcomes
1

Weight & body composition

1 endpoint
Secondary/protocol endpoint

Change in body weight

Time frame:From baseline to 12 weeks after treatment

Body weight, absolute change (kg)

change from baseline, improvement

Safety / tolerability / PK

2 endpoints
Secondary/protocol endpoint

Gastrointestinal side effects

Time frame:Throughout the treatment period

descriptive

Secondary/protocol endpoint

Treatment adherence

Time frame:Throughout the study duration

Discontinuation due to AE

descriptive

Other clinical outcomes

1 endpoint
Primary/protocol endpoint/low confidence

Change in taste perception and food preferences

Time frame:From baseline to 12 weeks after GLP-1 agonist treatment

change from baseline, improvement

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.